Key result
L-carnitine added to standard therapy for 6 weeks achieved absence of complaints and normalization of objective status in 93.3% of long COVID patients versus 66.7% with standard therapy alone (p<0.05).
Why the study?
To evaluate the effectiveness of L-carnitine in the complex correction of cardiovascular and autonomic manifestations of long COVID in children, adolescents, and young adults.
Does L-carnitine added to standard therapy improve cardiovascular and autonomic manifestations in children, adolescents, and young adults with long COVID?
RCT (n=90)
Open-label
randomized
Does L-carnitine added to standard therapy improve cardiovascular and autonomic manifestations in children, adolescents, and young adults with long COVID?
Absolute Event Rate: 93.3% vs 66.7%
p-value: p=<0.05
L-carnitine supplementation added to standard therapy significantly improves clinical symptoms, autonomic regulation, and echocardiographic parameters in young patients with long COVID.
May support adjunctive L-carnitine for long COVID symptoms in youth; extends RCT data to pediatric autonomic and cardiovascular effects.
The aim. To evaluate the effectiveness of L-carnitine in the complex correction of cardiovascular and autonomic manifestations of long COVID in children, adolescents, and young adults. Materials and methods. Within the framework of an open, simple, randomized, parallel-group comparative clinical study, the effectiveness of L-carnitine at a dose of 50–75 mg/kg per day in 2 doses for 6 weeks in addition to standard therapy in children and adolescents aged 10 to 17 years, as well as young people aged 18–25 years with long COVID ( n = 45) was studied in comparison with the standard therapy ( n = 45) using clinical and anamnestic, electrophysiological, echocardiographic and other methods. The statistical processing of the results was carried out by the variational method, and correlation and regression analysis using Student’s t -test for dependent samples, as well as the McNemar chi-square test. Results . The most frequent clinical manifestations of long COVID were: high fatigue, headaches and muscle weakness — in 66.7–100%. After 6 weeks of treatment, the absence of complaints and normalization of objective status were noted in 93.3% of patients in the main group and 66.7% in the comparison group ( p < 0.05). Repolarization abnormalities and rhythm disturbances, initially registered in 43.3% of patients, were not observed after 6 weeks of therapy in the main group, while they persisted in more than 50% in the comparison group. By the 6 weeks of treatment, there were no changes in Echo in the main group, while in the comparison group (slight dilatation of the left ventricle) persisted in 9 out of 12 patients. In the main group, according to Holter monitoring, restoration of heart rate, normalization of its autonomic regulation, reduction in the representation of bradyarrhythmias and “density” of extrasystoles were achieved. Conclusion. The effectiveness of L-carnitine for the correction of the frequency and severity of autonomic and cardiac disorders in the subjects with long COVID has been shown.
No takes yet. Share an insight, caveat, or question.
Балыкова et al. (2025) conducted an RCT in long COVID (n=90). L-carnitine vs. standard therapy was evaluated on absence of complaints and normalization of objective status (p=<0.05). L-carnitine added to standard therapy for 6 weeks achieved absence of complaints and normalization of objective status in 93.3% of long COVID patients versus 66.7% with standard therapy alone (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: